Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

In the Dog House: Chiron

January 2003

In the Dog House: Chiron Chiron Corporation, maker of interleukin-2 (IL-2), the most promising immunotherapy for HIV, for dropping the most important study of the drug without completing it. The company has given various excuses and reasons, but the bottom line is money and an intention to become less involved in HIV. Negotiations are underway to revive a streamlined version of the study, but Chiron continues to offer less financial support than needed.

Want to tell them how you feel about this? Write or email:
Sean P. Lance, CEO
Chiron Corporation
4560 Horton Street
Emeryville, CA 94608-2916
sean_lance@chiron.com


Back to the Project Inform Perspective January 2003 contents page.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement